Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

More recent case law has reinforced this principle, holding that when therapeutic and non-therapeutic effects are inseparably ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its investigational obesity drug, VK2735, as the biotech positions itself to ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its investigational obesity drug, VK2735, as the biotech positions itself to ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

Loopback Analytics, a leading provider of data-driven market access solutions for health system specialty pharmacies, today announced a strategic partnership with Ballad Health, a 20-hospital health ...

The findings are particularly relevant as the T1D market continues to evolve. (Image Credits: Pexel) A new study has revealed that off-label use of semaglutide (Ozempic) and tirzepatide (Mounjaro ...

This approach ensures end-to-end secure Zero Touch Network Access and high-performance ... of their favorite football team.... at 14:30 Oral semaglutide 14 mg demonstrated superior reduction in risk ...

CagriSema is a combination of cagrilintide — a nascent form of weight loss treatment known as an amylin analog — and ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...